Dogwood Therapeutics Inc. (DWTX) — RQD Stock Rating Cockpit

The Roarable RQD Score is 36 out of 100, with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). The five pillars are:

• Fundamental Cash Engine: 8 / 20. Per the Roarable RQD rating, this reflects ROIC of -32.3% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on capital or free cash flow, so value must rest on future operations rather than present earnings.
• Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is the second-lowest pillar and points to weak institutional support. Holder data is not available in the source data, so the drivers of this score cannot be independently examined here.
• Insider Conviction: 5 / 20. Per the Roarable RQD rating, this covers SEC Form 4 and Congressional PTR cluster flow. The score is low, which tempers any read-through from insider activity. Insider transaction detail is not available in the source data.
• Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. This is a middling score; the stock's price moves are, by this measure, in line with the broader market rather than amplified.
• Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, the Altman Z is 2.5, the Piotroski F is 2/9, and Debt/Equity is 0.5. A Piotroski F of 2 out of 9 is weak on the nine-point scale, and the balance sheet is judged middling rather than strong.

Taken together, the rating suggests a prospective investor faces negative operating economics, weak institutional and insider signals, and a balance sheet that is not a source of strength. Any upside case would depend on a catalyst that changes the cash-generation picture, such as trial progress or financing that extends runway, rather than on current fundamentals. Valuation tradeoffs are sharp: with no reported earnings or positive free cash flow, traditional multiples cannot be applied from the source data.

Dogwood Therapeutics Inc. (DWTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The source data does not describe specific products, customers, or revenue model. Reported revenue is $0.0M in each period shown in the SEC financials, so the company is not generating revenue in the reported periods. The source data does not detail how the company intends to monetize its development activities.

Per the SEC financials, operating losses and net losses widened across the three reported years, and cash declined from $14.8M to $6.5M between FY 2024 and FY 2025. Gross, operating, and net margins are reported as 0% (per the market data), consistent with zero revenue. ROIC is -32.3% (per the market data). Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Debt/Equity is 0.5 per the Roarable RQD rating, while debt is shown as N/A in the SEC financials; the source data does not reconcile these.

• Private placement (YELLOW, MARKET WIRE): A $5 million private placement with CK Life Sciences Int'l., (Holdings) Inc. is reported. Per the news item, the placement is described as expected to fund operations through March 2027 as the company plans its next pain-drug trial.
• Planned share sale (YELLOW, MARKET WIRE): A report states that stockholders plan to sell 4.1 million shares, with a 4.1M-share sale expected to close by October 29.
• Investor event (GREEN, CATALYST): The company plans to participate in the 2026 Maxim Growth Summit.
• Cash-usage commentary (YELLOW, MARKET WIRE): A Simply Wall St piece addresses the company's need to use its cash wisely.

Risk watch items: dilution risk from the private placement and the 4.1 million-share sale, and runway concerns given cash of $6.5M at FY 2025 year-end against FCF of $-15.6M in that year. Proprietary signals: none in the Butterfly Supply-Chain Graph.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations for DWTX. A prospective investor should note that the one identifiable second-order dependency is financing: the company's runway, as described in the news items, depends on the private placement and the timing of the planned share sale. Watch for how the 4.1 million-share sale affects supply and price, and for whether trial timing aligns with the stated funding horizon.

• What are the company's specific clinical programs, and what is the timing and scope of the planned pain-drug trial?
• Does the $5 million private placement's stated runway through March 2027 account for the trial costs, and what financing is needed beyond that date?
• Reported debt is N/A while Debt/Equity is 0.5 — what is the actual debt load and capital structure?
• Who are the stockholders planning the 4.1 million-share sale, and what is the expected price impact?
• What explains the sharp decline from a 52-week high of $7.04 to the current $1.23, and is it tied to operating or financing events?